June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
The role of IL-13 in the pathogenesis of ocular mucous membrane pemphigoid.
Author Affiliations & Notes
  • Suryanarayana Rayapureddi
    UCL Centre for Nephrology, University College London, London, United Kingdom
    UCL Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom
  • Jill Norman
    UCL Centre for Nephrology, University College London, London, United Kingdom
  • Valerie P J Saw
    Corneal and External Disease, Moorfields Eye Hospital, London, United Kingdom
    Ocular Biology and Therapeutics, UCL Institute of Ophthalmology, London, United Kingdom
  • David Abraham
    UCL Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom
  • John Kenneth George Dart
    Corneal and External Disease, Moorfields Eye Hospital, London, United Kingdom
    Ocular Biology and Therapeutics, UCL Institute of Ophthalmology, London, United Kingdom
  • Footnotes
    Commercial Relationships Suryanarayana Rayapureddi, None; Jill Norman, None; Valerie Saw, None; David Abraham, None; John Dart, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3039. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Suryanarayana Rayapureddi, Jill Norman, Valerie P J Saw, David Abraham, John Kenneth George Dart; The role of IL-13 in the pathogenesis of ocular mucous membrane pemphigoid.. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3039.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Ocular mucous membrane pemphigoid (OcMMP), a severe inflammatory autoimmune disease is characterised by conjunctival fibrosis leading to blindness. Current therapies fail to halt the progressive conjunctival scarring and there is a need for novel anti-fibrotic therapies. We previously reported the high expression of Interleukin-13 (IL-13) in OcMMP conjunctiva (Saw et al., Am J Pathol. 2009). We hypothesize that IL-13 plays a role in the pathogenesis of OcMMP, activating human conjunctival fibroblasts (HCF) to promote scarring, and that it may be a new therapeutic target.

Methods: HCFs were grown from conjunctival biopsies obtained from OcMMP patients and age-matched controls (5 patients/group). Expression of IL-13 receptors on HCFs was examined by flow cytometry. The effects of IL-13 on HCF function were measured using established fibrogenic assays: cell proliferation (BrdU incorporation), migration (scratch wound assay), collagen gel contraction and myofibroblast differentiation (expression of α-Smooth Muscle Actin by Western blotting and immunofluorescence). Gene expression profiling (Illumina Transcriptome Arrays) was done to identify IL-13 target genes. Cytokine production in response to IL-13 was assessed by Multiplex ELISA of HCF conditioned media.

Results: Both IL-13 receptors (IL-4α/IL-13Rα1; IL13Rα2) are expressed on HCFs with high levels of IL-13Rα1 (both groups) and variable IL13Rα2 expression (control-low; OcMMP-variable). IL-13 dose-dependently (5 - 50ng/ml) inhibits control HCF proliferation (p<0.05 in 4/5) but had no significant effect on OcMMP cells. IL-13 stimulates collagen gel contraction by control HCFs (% change after 7-days; p=0.025) but not by OcMMP cells (p=0.074). IL-13 had no effect on HCF migration or myofibroblast differentiation in either group. Both pro-inflammatory (Interleukin-6, Monocyte Chemoattractant Protein-1) and pro-fibrotic proteins (which regulate collagen biosynthesis and extracellular matrix (ECM) stability) were induced by IL-13 in both groups.

Conclusions: Our current data suggest that, although IL-13 has no direct pro-fibrotic effects on HCFs, IL-13 produced by T-cells may act to promote inflammation and sustain fibrosis through the induction of inflammatory cytokines and proteins involved in ECM synthesis and stability. Taken together, these data suggest that IL-13 inhibition may be an effective topical therapy to limit scarring in OcMMP patients.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×